ProShare Advisors’s Praxis Precision Medicines PRAX Stock Holding History

ProShare Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.41M	Sell	4,208 -780	-16%	-$247K	﹤0.01%	734
2026 Q1	$1.61M	Sell	4,988 -226	-4%	-$69.9K	﹤0.01%	715
2025 Q4	$1.54M	Buy	5,214 +1,388	+36%	+$258K	﹤0.01%	729
2025 Q3	$203K	Buy	+3,826	New	+$186K	﹤0.01%	1691
2025 Q1	–	Sell	-5,738	Closed	-$442K	–	2212
2024 Q4	$442K	Buy	+5,738	New	+$415K	﹤0.01%	1349
2022 Q2	–	Sell	-730	Closed	-$112K	–	2042
2022 Q1	$112K	Sell	730 -176	-19%	-$36.2K	﹤0.01%	2008
2021 Q4	$267K	Buy	+906	New	+$266K	﹤0.01%	1854

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ProShare Advisors's PRAX Position: Q2 2026 in Review

ProShare Advisors reduced its Praxis Precision Medicines (PRAX) stake by 16% in Q2 2026, selling an estimated $247K and leaving 4,208 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #734.

ProShare Advisors first reported a position in PRAX in Q4 2021 and has held it in 7 quarters since. The position peaked at $1.61M in Q1 2026. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

ProShare Advisors held 4,208 shares of Praxis Precision Medicines worth $1.41M as of Q2 2026.
ProShare Advisors sold 780 Praxis Precision Medicines shares in Q2 2026, an estimated $247K.
Praxis Precision Medicines made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #734 holding.
ProShare Advisors first reported a position in Praxis Precision Medicines in Q4 2021 and has held it in 7 quarters since.
ProShare Advisors's Praxis Precision Medicines position peaked at $1.61M in Q1 2026.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.